RASSF5A, a candidate tumor suppressor, is epigenetically inactivated in esophageal squamous cell carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• The RASSF5 gene exhibits alternative splicing, producing isoforms RASSF5A, RASSF5B, and RASSF5C, potentially involved in tumorigenesis.
• Understanding the specific roles of RASSF5 isoforms in esophageal squamous cell carcinoma (ESCC) pathogenesis is crucial.

Purpose of the Study:

• To investigate the roles of RASSF5A, RASSF5B, and RASSF5C in ESCC.
• To identify critical CpG sites in RASSF5A associated with its function in ESCC.

Main Methods:

• Analysis of RASSF5 isoform expression and methylation status in esophageal cancer cell lines and ESCC tissues.
• Treatment of cell lines with 5-Aza-dC (demethylating agent) and TSA (histone deacetylase inhibitor) to assess reversibility of gene silencing.
• Correlation analysis of RASSF5A methylation and protein expression with clinical data, including patient survival.

Main Results:

• Frequent silencing of RASSF5A, but not RASSF5B or RASSF5C, was observed in esophageal cancer cell lines.
• Aberrant CpG island 1 methylation of RASSF5A was identified as a cause of its silencing in TE13 cells.
• Decreased RASSF5A mRNA and protein expression in ESCC tissues correlated with RASSF5A CpG island 1 methylation.
• RASSF5A methylation and protein levels were independently associated with ESCC patient survival.
• No significant expression variation or aberrant promoter methylation was found for RASSF5B and RASSF5C in ESCC.

Conclusions:

• Inactivation of RASSF5A through CpG island 1 methylation plays a significant role in ESCC carcinogenesis.
• RASSF5A functions as a tumor suppressor in the context of ESCC.
• RASSF5A serves as a potential prognostic biomarker for ESCC.